Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma

Yoshiyuki Suzuki, Kousaku Mimura, Yuya Yoshimoto, Mitsuaki Watanabe, Yu Ohkubo, Shinichirou Izawa, Kazutoshi Murata, Hideki Fujii, Takashi Nakano, and Koji Kono.

1. Department of Surgery, National University of Singapore, Singapore
2. Department of Radiation Oncology, Gunma University Graduate School of Medicine, Japan
3. First Department of Surgery, University of Yamanashi, Japan
4. Cancer Science Institute of Singapore, Singapore

Address correspondence to: Koji Kono, PhD, MD
Department of Surgery, National University of Singapore
Level 8, NUHS Tower Block, 1E Kent Ridge Road, 119228 Singapore
Office phone +65 6772 3196    Fax +65 6777 8427
Email: surkoji@nus.edu.sg

Yoshiyuki Suzuki and Kousaku Mimura contributed equally to the present study.

Running title: Antigen-specific T cell response following chemoradiotherapy

Key words: HMGB1, Calreticulin, Immunogenic cell death, Chemoradiation, Esophageal squamous cell carcinoma, Cancer-Testis antigen

This work was supported by a grant from the Ministry of Education, Culture, Sports, Science and Technology in Japan.
There is no conflict of interest in the present study.

Word counts: Total 4717, Abstract 192
6 Figures and 1 Table
Abstract

Although it has been shown that chemoradiotherapy may induce immunogenic cell death, which could trigger T-cell immunity mediated by high-mobility group box 1 protein (HMGB1) and calreticulin, there is still limited information to support this theory directly in a clinical setting. In the present study, we evaluated antigen-specific T cell responses against 6 Cancer-Testis antigens in peripheral blood lymphocytes from patients with esophageal squamous cell carcinoma (ESCC) receiving chemoradiation. Expression of HMGB1 and calreticulin within tumor-microenvironment was also analyzed in resected samples with and without chemoradiotherapy in relation to patients survival. Tumor-antigen specific T cell responses were confirmed in 6 (38%) out of 16 ESCC patients after chemoradiotherapy coexisting with elevated serum HMGB1. In addition, HMGB1 within tumor-microenvironment was significantly up-regulated in ESCC patients with preoperative chemoradiotherapy, but not in those without chemoradiotherapy, and the degree of HMGB1 positively correlated with patient survival (n=88). Both irradiation and chemotherapeutic drugs induced up-regulation of HMGB1 and calreticulin in 9 ESCC cell lines. Furthermore, HMGB1 was able to induce maturation of dendritic cells. Together, our findings indicate that chemoradiation induces tumor-antigen specific T cell responses, and HMGB1 production is related to clinical outcome after chemoradiation.
Introduction

Esophageal squamous cell carcinoma (ESCC) is well known to be sensitive to radiotherapy and its combination with chemotherapy was proven to have clinical benefits (1, 2). It is generally accepted that irradiation is able to directly induce apoptosis or necrosis against ESCC and various strategies of radiotherapy, such as hyperfractionated irradiation (3) and image-guided radiotherapy (4), in order to enhance direct cytotoxic and cytostatic effects against ESCC through radiation oncology (5, 6). However, there is accumulating evidence to support the novel concept that radiotherapy with/without chemotherapy may induce immunogenic cell death, which could trigger uptake of antigenic components by dendritic cells (DCs) and transfer antigenic signals to T-cell mediated immunity, resulting in the expansion of antigen-specific cytotoxic T lymphocytes (CTLs) and production of tumor specific mAbs in murine models (7-14). It has been shown that the collaboration between the direct effects of irradiation and enhanced tumor-specific immunity induced by the irradiation could reject inoculated live tumors in murine models, where irradiation alone was not able to reject tumors (7, 8). Important mediators that induce immunogenic cell death include high-mobility group box 1 protein (HMGB1) and calreticulin induced by chemoradiation. For example, HMGB1 released from tumor cells treated with chemoradiation could enhance engulfment of antigenic components by DCs through toll-like receptor 4 (TRL4) and mediate cross-presentation of tumor antigens into CD4 and CD8 T cells (7-13). Also, early membrane exposure of calreticulin induced by irradiation could enhance phagocytosis of dying tumor cells by DCs (13, 15, 16), and calreticulin is related to autophagy-dependent
anticancer immune responses induced by chemotherapeutic agents (17).

However, there is limited information describing whether immunogenic cell death could be induced by radiotherapy or chemotherapy in clinical settings, probably due to the lack of accurate assay systems to evaluate antigen-specific T cell responses in cancer patients receiving chemoradiotherapy. We have recently identified several novel HLA-class I-restricted epitopes presented on ESCC and recognized by tumor-specific T cells through the genome-wide approach (18-20). Our gene expression profile data indicated that Cancer-Testis antigens such as TTK protein kinase (TTK), Lymphocyte antigen 6 complex locus K (LY6K), Cell division cycle associated 1 (CDCA1), 34kDa-translocase of the outer mitochondrial membrane (TOMM34), Hypoxia-inducible protein 2 (HIG2), and Insulin-like growth factor (IGF)-II mRNA binding protein 3 (IMP3) were highly expressed in ESCC (18-25). Peptides derived from these Cancer-Testis antigens could stimulate CTL that recognize and kill ESCC cells endogenously expressing these antigens (18, 19, 23). Furthermore, we have established a reliable in vitro assay system using peripheral blood lymphocytes (PBLs) to detect tumor-specific CTL responses against the panels of HLA class I epitopes derived from these Cancer-Testis antigens (18, 19). Therefore, it is possible to analyze antigen-specific T cell responses induced by chemoradiotherapy and evaluate the phenomenon "immunogenic cell death" in patients with ESCC receiving chemoradiotherapy. There is, to our knowledge, no previous report to directly prove antigen-specific T cell responses following chemoradiotherapy in clinical settings.
In the present study, we evaluated; (i) if chemoradiotherapy could induce antigen-specific T cell responses in ESCC patients, (ii) if chemoradiotherapy could up-regulate HMGB1 and calreticulin in in vivo and in vitro settings, and (iii) if expression of HMGB1 and calreticulin correlate to clinical outcomes.

Materials and Methods

Patients and samples

Study group-1

Sixteen HLA-A2402(+) or HLA-A0201(+) patients with histologically diagnosed primary ESCC who were treated at the Department of Radiation Oncology, Gunma University and the First Department of Surgery, University of Yamanashi Hospital were enrolled in this study. ESCC patients receiving chemoradiotherapy (15 men and 1 women, 64.5 ± 10.2 years old) were 4 patients in stage II, 6 patients in stage III, and 6 patients in stage IV according to the TNM classification for esophageal cancers (UICC, 5th edition). None of the patients had received any treatment before this study. Enrolled patients received definitive concurrent chemoradiotherapy (2Gy X 30-33 = total 60-66Gy and 5FU/CDGP or CDDP/Docetaxel-based chemotherapy). In order to evaluate the tumor-antigen specific T cell response after chemoradiation, peripheral blood samples (PBLs) were taken from patients during pre-chemoradiotherapy periods (within 1 week before chemoradiotherapy), during chemoradiotherapy (21 ± 3 days after the initiation of chemoradiotherapy), post-chemoradiotherapy day 3
(within 3 days after the termination of chemoradiotherapy), and post-chemoradiotherapy day 30 (30 ± 3 days after the termination of chemoradiotherapy). PBLs were isolated with Ficoll-Paque Plus (GE Healthcare Bio-sciences, Piscataway, NJ) density gradient solution and frozen in aliquots. This study and the use of all clinical materials were approved by the individual Institutional Ethical Committees, and written informed consent was obtained from all participants.

Study group-2
Formalin-embedded tumor samples from a total of 88 ESCC patients were evaluated in Study group-2. The clinical background of patients receiving preoperative chemoradiotherapy (n=45, 40Gy irradiation + concurrent 5Fu/CDDP/Docetaxel chemotherapy) and patients without preoperative chemoradiotherapy (n=43) were shown in Supplemental Table S1. This study and the use of all clinical materials were approved by the Institutional Ethical Committee, University of Yamanashi, and written informed consent was obtained from all participants.

**Cell lines and transfection**
Esophageal Squamous Cell Carcinoma (ESCC) cell lines, TE-1, TE-2, TE-3, TE-4, and TE-5 were obtained from the University of Tohoku cell bank (Institute of Development, Aging and Cancer, University of Tohoku, Sendai, JAPAN). ESCC cell lines, KYSE-30, KYSE-50, KYSE-70, and KYSE110 were purchased from the Health Science Research Resources Bank (Osaka, JAPAN). COS-7
cells were obtained from the American Type Culture Collection (Rockville, MD). The experiments were performed within less than 6 months after receipt from the cell bank. Cell lines were regularly authenticated and matched short tandem repeat DNA profiles of the original cell lines in each cell bank. All cell lines were maintained in RPMI 1640 with 5% FCS, 50U/ml penicillin, and 2 mM L-glutamine.

COS-7 cells were co-transfected with vectors expressing TTK, LY6K, IMP3, CDCA1, TOMM34, HIG2 in the combination of HLA-A2402, or HLA-A0201 using FuGENE6 (Roche, Indianapolis, IN) reagents (18). Thereafter, 3×10^5 cells/well were incubated in DMEM (Sigma) with 10% FCS, and 1% anti-mycobiotics (Sigma-Aldrich) in 6-well flat bottom plates (Becton Dickinson Labware, Franklin Lakes, NJ). 2 days after culture, cells were used as target cells in enzyme-linked immunospot (ELISPOT) assays as described below.

**In vitro T-cell culture and ELISPOT assay**

In Study group-1, PBLs (5×10^5 cells/well) obtained from different time points were simultaneously thawed and cultured in X-VIVO15 medium with 100 U/ml rIL-2 (Peprotech, Rocky Hill, NJ) in 48-well flat bottom plates (Becton Dickinson Labware) for 14 days without any antigen stimulation. On day 15, cultured cells were subjected to ELISPOT assays as responder cells.

To detect the antigen-specific T cell response, an ELISPOT assay was performed with the human Interferon-gamma (IFN-γ) ELISPOT kit (Mabtech, Nacka Strand, Sweden). 96-well plates with nitrocellulose membranes (Millipore, Molshelm, France) were pre-coated with primary anti-IFN-γ antibody (1-D1K) at
4 °C overnight. Plates were then pre-reacted with X-VIVO15 containing 1% human serum albumin (Sigma-Aldrich). COS-7 cells (2×10^3/well) transfected with individual genes (see above) and responder cells (2×10^3/well) were mixed and incubated in a final volume of 200 μl/well of X-VIVO15 for 24 hrs in triplicate. Cell mixtures were treated with biotinylated secondary anti-IFN-γ antibody (7-B6-1) and incubated for 2 hrs. Plates were then incubated with HRP-reagent and stained with TMB (Mabtech). Spots were quantified with the auto-analyzing system, KS ELISPOT Compact (ZEISS, Göttingen, Germany). Antigen-specific spots were the average of triplicates by subtracting target wells transfected with HLA-A molecule alone from target wells transfected with HLA-A molecule + tumor antigen molecules. Positivity of the tumor antigen-specific T cell response was defined when the number of antigen-specific spots was ≥ 200. We defined the assessable lower limit of spots per well as ≥ 20 spots.

Immunohistochemistry (IHC)

In Study group-2, HMGB1-, calreticulin-, CD8- and Foxp3-immunostainings were conducted using the avidin-biotin-peroxidase complex method. For HMGB1 and calreticulin, each paraffin section was dewaxed, followed by antigen retrieval with Target Retrieval Solution (10 mmol citrate buffer at pH 6.0, Dako) in an autoclave (121°C, 15 min). Sections were cooled at room temperature for 30 min and endogenous peroxidase was blocked with 3% hydrogen peroxide. Thereafter, sections were incubated with diluted normal blocking serum for 20 min, and incubated with rabbit anti-human HMGB1 mAb (Clone 2F6, Sigma-Aldrich, 3 μg/ml) overnight at 4°C or with mouse anti-human calreticulin
mAb (abcam, 5μg/ml) for 2 hrs at 37°C. Thereafter, peroxidase-linked secondary antibodies (Dako) and diaminobenzidine were used to detect specific binding. For Foxp3-staining, each paraffin section was dewaxed, followed by antigen retrieval with Epitope Retrieval Solution (10 mmol citrate buffer at pH 6.0, Dako) in a preheated water bath (98°C, 40 min), and endogenous peroxidase was blocked by Chemmate Peroxidase Blocking Solution (Dako). Then, biotinylated anti-human Foxp3 mAb (diluted by PBS at 1:20, eBioscience, San Diego, CA, USA) was applied for 40 min at room temperature. Thereafter, peroxidase-linked secondary antibodies and diaminobenzidine were used to detect specific binding.

For CD8-staining, each paraffin section was dewaxed, followed by antigen retrieval with Target Retrieval Solution (10 mmol citrate buffer at pH 6.0, Dako) with an autoclave (121°C, 15 min). The sections were cooled at room temperature for 30 min and endogenous peroxidase was blocked with 3% hydrogen peroxide. Thereafter, the sections were incubated with diluted normal blocking serum for 20 min, and incubated with diluted anti-human-CD8-mAb, Clone C8/144B (Dako), overnight at 4°C. Thereafter, peroxidase-linked secondary antibodies and diaminobenzidine were used to detect specific binding.

Quantitative evaluation of HMGB1- and calreticulin (membranous + intracellular)-positive cancer cells, and tumor-infiltrating CD8- and Foxp3-positive cells was carried out in serial sections using five randomly selected areas at a magnification of 400 X by two observers (S. I. and K.K.) in a blinded manner. The grade of HMGB1 and calreticulin expression was classified
into HMGB1-strong and HMGB1-weak, or calreticulin-strong and calreticulin-weak groups based on the median value of the counts of positive cancer cells.

**In vitro treatments of ESCC with irradiation and chemotherapeutic agents**

Nine ESCC cell lines (8 x 10^4/ml), TE-1, TE-2, TE-3, TE-4, TE-5, KYSE-30, KYSE-50, KYSE-70, and KYSE110 were incubated with 5% RPMI medium in 48 well plates and treated with 10Gy irradiation on day 1, day 2, and day 3 (total = 30Gy) or with combination chemotherapy of 5FU (2.5 ~ 10ng/ml) + CDDP (5 ~ 20 ng/ml) + Docetaxel (25 ~ 100 ng/ml) on day 1. Dying cells were analyzed by Annexin-V (BD Pharmingen, Franklin Lakes, NJ, USA) and 7-amino-actinomycin D (7-AAD) (BD Pharmingen) by flow cytometry and the proportion of dying cells was determined by either Annexin-V (+) or 7-ADD (+) cells. Supernatants of treated ESCC cultures were measured for HMGB1 contents by ELISA (Shinotest, Tokyo) and cell surface expression of calreticulin was evaluated by flow cytometry with RPE-conjugated anti-calreticulin mAb (Enzo life Sciences, NY, USA).

**Treatment of DCs with HMGB1**

PBMCs from healthy volunteers (n=5) were separated by a Ficoll-Paque Plus density gradient and monocytes were separated from PBMCs by plastic adherences. Monocytes (3.0 x 10^5 /ml) were cultured in 6-well flat bottom plates (Becton Dickinson Biosciences) with 500 units/ml of GM-CSF (Peprotech EC, London, UK) and 500 units/ml of IL-4 (Peprotech) in X-VIVO. On day 5,
immature DCs were treated with recombinant HMGB-1 (10 μg/ml, R&D SYSTEMS, NM USA) or 10 μg/ml of OK-432 (Chugai, Tokyo). On day 7, immature DCs, HMGB1-treated DCs, and OK-432-treated DCs were analyzed with FACS using anti-human HLA-ABC FITC mAb (eBioscience, San Diego, CA), FITC-mouse anti-human HLA-DR, DP, DQ mAb (BD Pharmingen, NJ USA), FITC-mouse anti-human CD80 mAb (BD Pharmingen), APC-mouse anti-human CD83 mAb (BD Pharmingen), and PE-mouse anti-human CD86 mAb (BD Pharmingen).

**Statistical analysis**

Differences between values were determined using the paired and non-paired Student’s t-test. Overall survival (OS), which was measured in days from surgery to death or from chemoradiotherapy to death, was analyzed by the Kaplan-Meier method, and statistical differences were analyzed by the Log-rank method. All statistical analyses were performed with SPSS statistics 17.0 (SPSS Inc.). Significance was considered at \( p < 0.05 \).

**Results**

*Antigen-specific T cell response after chemoradiotherapy*

In Study group-1, PBLs obtained from before, during, and after chemoradiotherapy were cultured for 14 days *in vitro* and cultured T cells were subjected to an IFN-\( \gamma \) ELISPOT assay as responder cells.

As shown in Figure 1A, a representative ELISPOT assay (Case 10, HLA-A0201
(+ and HLA-A2402 (-)) indicated that in vitro cultured T cells from post-chemoradiation day 3 significantly reacted with COS transfected with IMP3 + HLA-A0201 or CDCA1 + HLA-A0201 and did not in those transfected with HLA-A0201 alone. In summarized data from Case 10 at different time points, antigen-specific T cell responses were significantly induced against COS transfected with IMP3, CDCA1, TOMM34, and HIG2 in combination with HLA-A0201 during chemoradiotherapy (Figure 1B), while there was no specific T cell response before chemoradiotherapy. These antigen-specific T cell responses tended to last until post-chemoradiation day 3, although these specificities diminished post-chemoradiation day 30 (Figure 1B). Moreover, there was no specific T cell response against COS transfected with target genes + HLA-A2402 before and after chemoradiation, in line with the patient being HLA-A2402 negative (Figure 1B). Thus, the results indicated that the tumor-antigen specific T cell response was induced by chemoradiotherapy in a patient with ESCC.

As shown in Figure 1C, a representative ELISPOT assay (Case 2, HLA-A0201 (-) and HLA-A2402 (+)) indicated that in vitro cultured T cells from post-chemoradiation day 30 significantly reacted with COS transfected with IMP3 + HLA-A2402 or LY6K + HLA-A2402 and did not in those transfected with HLA-A2402 alone. In summarized data from Case 2 at different time points, antigen-specific T cell responses were significantly induced against COS transfected with CDCA1 or LY6K in combination with HLA-A2402 at post-chemoradiation day 3, and against COS transfected with IMP3, TTK, or LY6K in combination with HLA-A2402 at post-chemoradiation day 30 (Figure 1D),
while there was no specific T cell response before chemoradiation. Moreover, there was no specific T cell response against COS transfected with target genes + HLA-A0201, in line with this patient being HLA-A0201 negative (Figure 1D). Taken together, the results of 6 (38%) out of 16 patients in Study group-1 revealed that antigen-specific T cell responses were significantly induced by chemoradiotherapy (Table 1).

When OS was compared between the patients with (n=6) and without (n=10) antigen-specific T cell responses, there was no significant difference in the OS between them (p = 0.212, Supplemental Figure S1).

**Serum HMGB1 levels after chemoradiotherapy**

Since HMGB1 is thought to be one of the mediators linking chemoradiation-induced cell death to antigen-specific T cell responses, serum HMGB1 levels (n=14) were evaluated before and after chemoradiotherapy (post-chemoradiation day 3) in Study group-1. As shown in Figure 2A, increased levels of HMGB1 were significantly observed after chemoradiotherapy, while there was no detectable level of HMGB1 before chemoradiotherapy. There was no significant correlation between the amount of serum HMGB1 at post-chemoradiation day 3 and number of spot-forming cells in ELISPOT assay against each antigen, which is corresponding to the grade of tumor-antigen specific T cell responses (Supplement Figure S2). However, when the amount of serum HMGB1 was compared between the patients with and without antigen-specific T cell responses following chemoradiation, the level of HMGB1 in the patients with antigen-specific T cell responses was significantly elevated in
comparison to that in the patients without antigen-specific T cell responses (18.1 ± 14.1 vs. 5.1 ± 4.9 ng/ml, Figure 2B), suggesting that HMGB1 produced by chemoradiation play an important role in inducing systemic tumor antigen-specific T cell responses.

**HMGB1 and calreticulin expression induced by chemoradiotherapy**

In order to evaluate HMGB1 and calreticulin expression within tumor microenvironments induced by chemoradiotherapy, immunohistochemical analysis was performed in resected tumor samples from Study group-2 between patients with (n=45) and without preoperative chemoradiotherapy (n=43). There was no difference in the background of patients except for the grade of lymph node dissection (Supplemental Table S1).

Representative immunostainings using anti-HMGB1 and anti-calreticulin mAbs in serial sections are shown in Figure 3. The grade of HMGB1 and calreticulin expression was classified into HMGB1-strong (Figure 3A) and HMGB1-weak (Figure 3B), or calreticulin-strong (Figure 3B) and calreticulin-weak (Figure 3A) groups based on the median value of the counts of positive tumor cells. Of note, the proportion of HMGB1-strong patients was significantly more predominant in the group with preoperative chemoradiotherapy than that without preoperative chemotherapy (Figure 4A). On the other hand, the distribution of calreticulin-strong and calreticulin-weak did not differ between groups with and without preoperative chemoradiotherapy (Figure 4A). Thus, it is suggested that chemoradiation up-regulated HMGB1 expression, but not calreticulin expression, more progressively in tumor microenvironments with ESCC.
In order to further evaluate the significance of HMGB1 in relation to T-cell immunity, the tumor-infiltrating grade of CD8- and regulatory T-cells were analyzed by immunohistochemistry in serial sections and compared between HMGB1-strong and -weak groups. Representative immunostainings using anti-CD8 and anti-Foxp3 mAbs are shown in Figure 3A and 3B. As shown in Figure 4C, summarized data indicated that there was a tendency of increased infiltrating CD8 (+) cells in the HMGB1-strong group (189 ± 92 cells/field) in comparison to those in the HMGB-weak group (140 ± 62 cells/field), although the difference did not reach a significant level (p = 0.065). There was no difference in the infiltrating grade of regulatory T cells (Foxp3-positive cells) between HMGB1-strong and -weak groups (Figure 4B). Moreover, when the infiltrating grade of CD8 (+) cells was compared between the calreticulin-strong and -weak groups, there was no significant difference (153 ± 79 vs. 149 ± 89 cells/field, respectively).

**HMGB1 and calreticulin expression relating to the survival**

As shown in Figure 5A, overall survival (OS) in the HMGB1-strong group was significantly superior to that in the HMGB1-weak group in total patients (n=88), patients without preoperative chemoradiotherapy (n=43), and patients with preoperative chemoradiotherapy (n=45). On the other hand, there were no significant differences in OS between calreticulin-strong and calreticulin–weak groups in total patients, patients without preoperative chemoradiotherapy, and patients with preoperative chemoradiotherapy (Figure 5B).
Thus, up-regulation of HMGB1 may be one of the phenotypes of ESCC with better survival.

In vitro treatment of ESCC with anti-cancer drugs or irradiation

In order to further evaluate HMGB1 and calreticulin expression following irradiation and chemotherapy, 9 ESCC tumor cell lines were treated with 30Gy irradiation or a combination of 5FU + CDDP + Docetaxel in vitro and, the production of HMGB1 and surface expression of calreticulin, along with the proportion of dying cells, were analyzed. There was no significant amount of HMGB1 in supernatants from any ESCC without irradiation or chemotherapy (Supplemental Figure S3). As shown in Figure 6 and Supplemental Figure S3, irradiation could induce variable levels of HMGB1 production depending on the cell line, for example, TE2 and KYSE70 produced substantial amounts of HMGB1 after irradiation, while TE4 and KYSE110 did not produce HMGB1 even though these cell lines underwent cell death by irradiation (The proportion of Annexin-V (+) or 7-ADD (+) cells were 75-95%). Similarly, chemotherapeutic drugs induced different levels of HMGB1 production among 9 ESCCs, however, the production levels of HMGB1 were relatively less than those induced by irradiation regardless of almost the same amount of dying cells (Figure 6 and Supplemental Figure S3).

With respect to calreticulin expression, both irradiation and chemo-drugs could up-regulate surface calreticulin more than the non-treatment controls (Supplemental Figure S3 and S4). As shown in Figure 6 and Supplemental Figure S3, irradiation could up-regulate calreticulin depending on the cell line, for
example, TE4 and KYSE30 revealed increased levels of calreticulin after irradiation, while the others did not show a dramatic up-regulation. Again, chemo-drugs could induce increased calreticulin expression among 9 ESCCs, however, up-regulated levels of calreticulin were relatively less than those induced by irradiation regardless of almost the same amount of dying cells (Figure 6 and Supplemental Figure S3).

Taken together, although both irradiation and chemo-drugs could induce up-regulation of HMGB1 and calreticulin on ESCCs, there were remarkable variations of the amounts increased depending on cell lines. Interestingly, irradiation could up-regulate HMGB1 and calreticulin more remarkably than chemotherapeutic drugs regardless of almost the same amount of dying cells.

Maturation of DCs treated by HMGB1

In order to confirm whether HMGB1 could maturate DCs, which is a crucial step for induction of antigenic T cell responses, monocyte-derived immature DCs were treated with HMGB1 and their maturation markers were evaluated by flow cytometry. Representative data from 5 different donors indicated that increased expression of maturation markers such as MHC class I, CD83, and CD86 on DCs was seen after treatment with HMGB1 in comparison to immature DCs, and the increased levels after treatment with HMGB1 were slightly less than mature DCs treated by OK-432 (26) (Supplemental Figure S5). These observations were confirmed in 5 independent experiments from different donors.
Discussion

The present study contains novel findings to support the concept of “immunogenic cell death induced by chemoradiotherapy in patients with ESCC”. First, tumor-antigen specific T cell responses were confirmed in 6 (38%) out of 16 ESCC patients following chemoradiotherapy. Second, the serum level of HMGB1 following chemoradiation in the patients with antigen-specific T cell responses was significantly elevated in comparison to that in the patients without antigen-specific T cell responses. Third, up-regulation of HMGB1 within tumor-microenvironments was significantly related to preoperative chemoradiotherapy and the degree of HMGB1 positively correlated with patients’ survival. Fourth, both irradiation and chemo-drugs could induce up-regulation of HMGB1 and calreticulin on ESCC cell lines in vitro. Finally, HMGB1 was able to induce maturation of DCs in an in vitro culture system.

In general, chemoradiotherapy is thought to induce an immunosuppressive state in both T cell- and NK cell-immunity and there has been a general consensus that systemic immunity in patients receiving chemoradiotherapy was severely impaired, leading to infectious complications and growth of residual tumors (27, 28). Also, many chemotherapeutic drugs or radiotherapy mediated their cytotoxic effects by the induction of apoptosis, and this apoptosis was generally considered to be non-inflammatory and non-immunogenic (29, 30). However, it has been recently shown that danger signals from dying cells treated by some chemotherapeutic drugs, such as oxaliplatin, or radiotherapy could induce TLR-dependent, antigen-specific T-cell immunity, as it has been shown that
chemoradiation could not reject inoculated live tumors in $tlr4^{-/-}$ mice, while chemoradiation could reject the tumors in wild-type mice (7, 8). Furthermore, among various danger signals released from dying cells in the tumor-bearing mouse model, HMGB1, but not other known TLR4 ligands, could be a mandatory factor to induce tumor-antigen specific T cell immunity (7, 8). It has also been shown that HMGB1 released from radiation-induced tumor cell death could enhance engulfment of antigenic components by DCs through TRL4 and mediate cross-presentation of tumor antigens into CD4 and CD8 T cells, effectively leading to tumor-antigen specific T cell responses in murine model (7, 8). In the present study, we showed for the first time in a human clinical study that tumor-antigen specific T cell responses were induced in ESCC patients following chemoradiation along with elevated HMGB1 in patients` serum. Furthermore, our IHC study clearly indicated that HMGB1 production within tumor-microenvironments was significantly related to preoperative chemoradiotherapy and the degree of HMGB1 positively correlated with patients` survivals. Furthermore, infiltrating grade of CD8(+) T-cells within tumor-microenvironments tended to be up-regulated in HMGB1 high-expressing group. Taken together, these observations in clinical settings strongly support the fact that immunogenic cell death is induced by chemoradiotherapy in patients with ESCC and HMGB1 is one of the important mediators linking chemoradiation-induced cell death to antigen-specific T cell responses.

Moreover, it has been shown that early membrane exposure of calreticulin induced by radiation could enhance phagocytosis of dying tumor cells by DCs in
vitro (13, 15, 16), and both HMGB1 release and calreticulin cell surface expression are required for antigen-specific T cell response in murine model. However, we could not show any significant differences in calreticulin expression between patients with and without chemoradiation, and there was no survival difference between calreticulin-strong and -weak groups. Moreover, the infiltrating grade of CD8(+) T-cells did not differ between calreticulin-strong and -weak groups. Thus, there is a discrepancy between murine model and clinical setting in terms of significance of calreticulin expression in relation to T-cell immunity or in relation to chemoradiotherapy. There is one possible explanation that we classified both membranous and intracellular staining as a positive case by immunohistochemistry (IHC) in the present study, since differentiation of staining pattern between membranous and intracellular was difficult in the IHC setting of clinical samples. Kroemer et al. previously reported that membranous expression of calreticulin was more relevant than intracellular global expression when immunogenic tumor cell death occurred in murine model (16). Further study with different methodology to evaluate the cell surface expression of calreticulin in clinical samples will be needed.

Of interest, we showed that chemoradiation could induce up-regulation of HMGB1 with significant variations among ESCC patients in Study group-2, and patients with high HMGB1 expression had better OS than patients with weak HMGB1 expression. Also, the in vitro study indicated that there were substantial variations in HMGB1 production following chemoradiation depending on ESCC cell lines regardless of almost the same amount of dying cells. These
observations suggest that immune reactions related to HMGB1 production following chemoradiation may affect clinical outcomes in ESCC patients. Apetoh et al. reported that patients with breast cancer with a TLR4 loss-of-function allele relapse more quickly after chemotherapy and radiotherapy than those with a normal TLR4 allele (8), indicating a clinically relevant immune reaction triggered by chemotherapy-induced cell death. Thus, these observations strongly indicated that the HMGB1-related immune response after chemoradiotherapy may play an important and critical role in clinical outcome of cancer treatments, and parameters such as HMGB1 expression and TLR polymorphism may be able to predict clinical outcome after chemoradiation.

There are some debates regarding the capability of HMGB1 to mature DCs. It has been shown that HMGB1 has an ability to promote DC activation and trigger DC migration in human DC in vitro (31), in line with our present study. On the contrary, Apetoh et al. reported there was no clear evidence that HMGB1 is required for the maturation of human DCs in immunogenic tumor cell death system (8). The discrepancy may be explained by the different protocol of DC-induction and -maturation including dose and timing of HMGB1. The exact mechanism by which HMGB1-TLR4 interactions affect the tumor-antigen presentation on DCs in immunogenic tumor cell death has not be clarified yet.

In conclusion, the present study strongly indicated that tumor-antigen specific T cell responses were induced following chemoradiation and HMGB1 production is related to clinical outcome after chemoradiation.
References


23. Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H. Identification of


28. Takagi K, Yamamori H, Furukawa K, Miyazaki M, Tashiro T. Perioperative supplementation of EPA reduces immunosuppression induced by


<table>
<thead>
<tr>
<th>Patient</th>
<th>HLA-A</th>
<th>Tumor specific antigens</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A2402</td>
<td>A0201</td>
</tr>
<tr>
<td>1</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>★</td>
<td>+</td>
</tr>
<tr>
<td>3</td>
<td>★</td>
<td>+</td>
</tr>
<tr>
<td>4</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>★</td>
<td>+</td>
</tr>
<tr>
<td>6</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>★</td>
<td>+</td>
</tr>
<tr>
<td>11</td>
<td>★</td>
<td>★</td>
</tr>
<tr>
<td>12</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>★</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>★</td>
<td>+</td>
</tr>
<tr>
<td>16</td>
<td>★</td>
<td>+</td>
</tr>
</tbody>
</table>

★ HLA-A allele type in the patients with esophageal squamous cell carcinoma receiving chemoradiotherapy.

+ The positive T cell responses specific for the indicated antigens evaluated by ELISPOT assay in patients’ peripheral blood lymphocytes following chemoradiotherapy.
**Figure legends**

**Figure 1. Tumor-antigen specific T cell responses after chemoradiotherapy**
In Study group-1, PBLs obtained before (Pre), during (During), and after (Post-3 and Post-30) chemoradiotherapy and COS-7 cells transfected with tumor antigens (TTK, LY6K, IMP-3, CDCA1, TOMM34, and HIG2) + HLA-A molecules (HLA-A2402 or HLA-A0201) were subjected to IFN-γ ELISPOT assays. A representative ELISPOT assay (Case 10, HLA-A0201 (+) and HLA-A2402 (-)) is shown on post-chemoradiotherapy day 3 (A) and summarized data from Case 10 at different time points are shown (B). A representative ELISPOT assay (Case 2, HLA-A0201 (-) and HLA-A2402 (+)) is shown on post-chemoradiotherapy day 30 (C) and summarized data in Case 2 at different time points are shown (D).

Pre, pre-chemoradiation periods; During, during chemoradiation; Post-3, post-chemoradiation day 3; Post-30, post-chemoradiation day 30

**Figure 2. Serum HMGB1 level in the patients receiving chemoradiotherapy**
(A), serum from patients (n=14) at pre-chemoradiation periods (Pre) and post-chemoradiation 3rd day (Post) were analyzed by ELISA assays specific for HMGB1. (B), serum levels of HMGB1 at post-chemoradiation 3rd day are compared between the patients with (CTL(+)) and without antigen-specific T cell responses (CTL(-)) evaluated by ELISPOT assay.

**Figure 3. Representative immunostainings for HMGB1, calreticulin, CD8 (+)**
cells and regulatory T cells.

Representative immunostainings using anti-HMGB1, anti-calreticulin, anti-CD8, and anti-Foxp3 mAbs in serial sections from 2 different patients are shown in Figure 3A and 3B.

Figure 4. Immunohistochemical analysis for HMGB1, calreticulin, CD8 (+) cells and regulatory T cells.

Immunohistochemical analysis was performed in resected tumor samples from Study group-2. The grade of HMGB1 and calreticulin expression was classified into HMGB1-strong and HMGB1-weak, or calreticulin-strong and calreticulin-weak groups based on the median value of the counts of positive cells within tumors. HMGB1 and calreticulin expressions on tumors between patients with preoperative chemotherapy (n=45, Operation + NeoCRT) and without preoperative chemoradiotherapy (n=43, Operation alone) are shown in 4A. The grade of tumor-infiltrating CD8 (Figure 4C) and regulatory T cells (Foxp3, Figure 4B) are shown.

Figure 5. HMGB1 and calreticulin expression relating to survival.

OS in Study group-2 are shown in total patients (n=88, Total), patients without preoperative chemoradiotherapy (n=43, Operation alone), and patients with preoperative chemoradiotherapy (n=45, Operation + NeoCRT) in terms of HMGB1 (A) and calreticulin (B) expression. The grade of HMGB1 and calreticulin expression was classified into HMGB1-strong and HMGB1-weak, or calreticulin-strong and calreticulin-weak groups based on the median value of
the counts of positive cells within tumors.

**Figure 6. In vitro treatment of ESCC with chemo-drugs or irradiation.**

Nine ESCC tumor cell lines were treated with 30Gy (10Gy irradiation on day 1, day 2, and day 3) radiation or a combination of 5FU + CDDP + Docetaxel on day 1 and analyzed on day 5. Contents of HMGB1 in the supernatant were evaluated by ELISA, and surface expression of calreticulin along with the proportion of dying cells (Annexin-V (+) or 7-ADD (+) ) were analyzed by flow cytometry.
Figure 1

(A) IMP3 + A0201 vs. A0201 alone

(B) A0201

(C) CDCA1 + A0201 vs. A0201 alone

(D) A2402

(E) IMP3 + A2402 vs. A2402 alone

(F) LY6K + A2402 vs. A2402 alone

Figure 1
Figure 2

(A) Serum HMGB1

ng/ml

70
60
50
40
30
20
10
0

p < 0.05

n = 14

Pre Post

(B) Serum HMGB1

ng/ml

70
60
50
40
30
20
10
0

p < 0.02

CTL(+) (n=6) CTL(-) (n=8)
Figure 3

(A) Calreticulin and HMGB-1 staining with Foxp3 and CD8 highlights.

(B) HMGB-1 and Calreticulin with Foxp3 and CD8.
**Figure 4**

### (A)

<table>
<thead>
<tr>
<th></th>
<th>HMGB-1 (n=88)</th>
<th></th>
<th>HMGB-1 (n=88)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Weak (n=42)</td>
<td>Strong (n=46)</td>
<td></td>
</tr>
<tr>
<td>Operation alone</td>
<td>28</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>Operation + NeoCRT</td>
<td>16</td>
<td>29</td>
<td></td>
</tr>
</tbody>
</table>

*p = 0.04 (χ² test)*

### (B)

<table>
<thead>
<tr>
<th></th>
<th>Calreticulin (n=88)</th>
<th></th>
<th>Calreticulin (n=88)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Weak (n=47)</td>
<td>Strong (n=41)</td>
<td></td>
</tr>
<tr>
<td>Operation alone</td>
<td>23</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Operation + NeoCRT</td>
<td>24</td>
<td>21</td>
<td></td>
</tr>
</tbody>
</table>

*p = 0.85 (χ² test)*

### (C)

<table>
<thead>
<tr>
<th></th>
<th>/field</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foxp3</td>
<td></td>
</tr>
<tr>
<td>HMGB1 weak</td>
<td>60</td>
</tr>
<tr>
<td>HMGB1 strong</td>
<td>40</td>
</tr>
</tbody>
</table>

*p = 0.065*

<table>
<thead>
<tr>
<th></th>
<th>/field</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD8</td>
<td></td>
</tr>
<tr>
<td>HMGB1 weak</td>
<td>300</td>
</tr>
<tr>
<td>HMGB1 strong</td>
<td>400</td>
</tr>
</tbody>
</table>
Figure 5

(A) Total (n=88) Operation alone (n=43) Operation + NeoCRT (n=45)

- HMGB-1 strong
- HMGB-1 weak

(B) Total (n=88) Operation alone (n=43) Operation + NeoCRT (n=45)

- Calreticulin strong
- Calreticulin weak

p < 0.05
p < 0.01
p < 0.05
NS
NS
NS

on April 14, 2017. © 2012 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Author Manuscript Published OnlineFirst on June 14, 2012; DOI: 10.1158/0008-5472.CAN-12-0851
Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma

Yoshiyuki Suzuki, Kousaku Mimura, Yuya Yoshimoto, et al.

Cancer Res  Published OnlineFirst June 14, 2012.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-12-0851

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2012/06/14/0008-5472.CAN-12-0851.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.